What Stragen does

Stragen is a privately-held Swiss pharmaceutical company headquartered in Geneva, founded in 1990 by Jean-Luc Tetard, who continues to serve as CEO. The company develops, registers, and distributes generic medicines and consumer healthcare products across three product categories: Critical Care (hospital medicines for oncology, cardiology, neurology, infectious diseases and antifungals), Woman Health (oral contraceptives and endometriosis treatments), and Consumer Health (natural formulations for fertility, immunity, and metabolic disorders). Its core technology focus is on hard-to-make, high added-value and niche hospital medicines with specialized pharmaceutical forms and dosages tailored to hospital practices, supported by a dedicated scientific team operating under European manufacturing with an eco-responsible approach.

The company operates a sales-led, B2B-oriented go-to-market model, distributing products through 7 wholly-owned regional affiliate offices covering Denmark, Finland, Germany, Spain, France, the UK, and Saudi Arabia, reaching approximately 60 markets and 77% of the European population. Revenue is generated through one-time license-based sales of generic and specialty medicines to hospitals, healthcare professionals, and (in the consumer health category) end consumers via prescription and retail channels. Pricing is not publicly disclosed and varies by market and reimbursement system.

Stragen's subsidiary structure includes Stragen Global (headquarters operations), Stragen Nordic, Stragen Finland, Stragen GmbH (Germany), Stragen España, Stragen France, Stragen UK, and Stragen العربية (Arabia/Saudi Arabia). The company remains founder-controlled with no evidence of external institutional investment, M&A activity, or public listing. No financial figures, funding rounds, or AI/technology platform capabilities are disclosed in the available data.

Name

Stragen

Legal name

Stragen

Website

https://www.stragen.ch/news/

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

Stragen is a Swiss private pharmaceutical company, founded in 1990, that develops, registers, and distributes generic medicines and consumer healthcare products across 60 markets via 7 regional affiliates, serving hospitals, healthcare professionals, and patients in Europe and the Middle East.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Specialty Care Pharmaceuticals (HLAIAAAB), Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK)

Keywords

• Generic pharmaceuticals
• Hospital medicines
• Women's health products
• Consumer healthcare
• Pharmaceutical distribution

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Generic Medicines Distribution: Development, registration, and distribution of generic medicines for hospital and retail use across therapeutic areas including oncology, cardiology, neurology, infectious diseases and antifungals.
2. Consumer Healthcare Products: Natural formulations for consumer health including fertility, immunity and metabolic disorders. Products include oral contraceptives and treatments for endometriosis.
3. Hospital/Prescription Medicines: Specialized hospital portfolio focusing on critical care therapeutic areas with unique dosages and pharmaceutical forms tailored to hospital practices.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Stragen develops, registers, and distributes generic medicines and consumer healthcare products, with a particular focus on hard-to-make, high added-value, and niche hospital medicines. Its portfolio is organized into three segments—Critical Care (oncology, cardiology, neurology, infectious diseases, antifungals), Woman Health (oral contraceptives, endometriosis), and Consumer Health (natural formulations for fertility, immunity, metabolic disorders)—manufactured in Europe under an eco-responsible approach.

Product overview

Stragen offers a unified portfolio of generic medicines and consumer healthcare products organized across three main categories: Critical Care (hospital medicines for oncology, cardiology, neurology, infectious diseases and antifungals), Woman Health (oral contraceptives and endometriosis treatments), and Consumer Health (natural formulations for fertility, immunity and metabolic disorders). All products are manufactured in Europe with an eco-responsible approach, targeting healthcare professionals and patients with innovative therapeutic solutions including hard-to-make, high-added-value and niche hospital medicines.

Differentiator

Problem solved

Functional benefit

Brands

• Critical Care: Hospital portfolio focusing on therapeutic areas: oncology, cardiology, neurology, infectious diseases and antifungals.
• Woman Health
• Consumer Health

Products and services

• Critical Care Hospital-focused generic medicine portfolio covering oncology, cardiology, neurology, infectious diseases, and antifungals, providing innovative therapeutic solutions with unique dosages and pharmaceutical forms tailored to hospital practices for healthcare professionals and hospital buyers.
• Woman Health Women's health product line including a range of oral contraceptives and products designed to address endometriosis-related issues, targeted at prescribers, pharmacies, and women's health clinics.
• Consumer Health Consumer healthcare products consisting of natural formulations crafted from carefully selected active ingredients based on scientific evidence, with expertise in fertility, immunity, and metabolic disorders for end consumers and consumer health distributors.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Healthcare ProfessionalscoreOthersStragen provides daily support for healthcare professionals by providing them with innovative therapeutic solutions, sometimes unique with dosages and pharmaceutical forms tailored to hospital practices.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Aspen Pharmacare: South African-headquartered specialty pharmaceutical group with established European footprint and a portfolio spanning hospital specialty and women's health — comparable in multi-region affiliate model and therapeutic mix.
• Gedeon Richter: Hungarian specialty pharmaceutical company with significant women's health (contraceptives, gynecology) and specialty generics franchises across Europe — directly comparable to Stragen's combination of women's health and hard-to-make generics.
• KRKA: Slovenian generics manufacturer with broad European footprint and a portfolio spanning hospital and consumer health segments, built around cost-efficient European manufacturing — comparable business model to Stragen.
• Stada Arzneimittel: German-headquartered European specialty generics and consumer health company with a multi-country affiliate model and broad hospital/retail portfolio — closely mirrors Stragen's combination of specialty generics plus consumer health verticals across European markets.
• Theramex: UK-based specialty pharma dedicated to women's health (contraception, menopause, endometriosis-adjacent therapies) — closely overlaps with Stragen's Woman Health vertical of oral contraceptives and endometriosis products.
• Exeltis: Global women's health pharmaceutical company with strong European presence in contraception and gynecology — comparable to Stragen's Woman Health segment in target therapeutic areas and customer base.
• Zentiva: European generics company headquartered in Prague, with a multi-country affiliate model across Central and Western Europe focused on affordable medicines — closely comparable in geographic and channel strategy to Stragen.

Broad incumbents

• Viatris: Global generics and specialty pharmaceutical major formed via Mylan-Upjohn combination, with broad European hospital and retail presence — a much larger incumbent operating in the same generic and specialty pharma space as Stragen.
• Sandoz: Novartis's generics and biosimilars division, with leading European hospital generics business and global distribution — operates in the same hospital generics category as Stragen but at significantly greater scale.
• Teva Pharmaceutical Industries: World's largest generics manufacturer with deep European presence across specialty, hospital, and women's health categories — broad incumbent overlapping with Stragen's therapeutic and geographic scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stragen